🔎 Trials Near Me

Home › Blood Cancers › Oregon

Blood Cancers clinical trials in Oregon

8 studies for Blood Cancers are looking for participants at sites in Oregon.

Cities in Oregon

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Saint Alphonsus Cancer Care Center-Baker City, Baker City
  • Saint Charles Health System, Bend
  • Clackamas Radiation Oncology Center, Clackamas
  • and 7 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069

Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects

  • Saint Alphonsus Cancer Care Center-Baker City, Baker City
  • Saint Charles Health System, Bend
  • Clackamas Radiation Oncology Center, Clackamas
  • and 9 more
RecruitingObservational study
All ages · All sexes · Updated Sep 17, 2026 · NCT04242095

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • Willamette Valley Cancer Institute, Eugene
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07007312

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • Oregon Health and Science University, Portland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Oregon Health & Science University/Doernbecher Children's Hospital, Portland
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545

IVIG for Infection Prevention After CAR-T-Cell Therapy

  • Oregon Health and Science University (OHSU) Knight Cancer Institute, Portland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05952804

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • Providence Neurological Specialties West, Portland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT03328078

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Oregon Health & Science University, Portland
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.